Ph.D. Michael Exton - 12 Feb 2026 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: LXRX
Reported as of: 12 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Feb 2026, 16:05:31 UTC
Prior SEC filing: 18 Feb 2025
Next SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Exton, Ph.D.

Key filing fact

Ph.D. Michael Exton filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 17 Feb 2026.

Key facts

This page summarizes Ph.D. Michael Exton's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Feb 2026, 16:05.

Change

Previous filing in this sequence was filed on 18 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002029249 Primary reporting owner

Exton Michael

Relationship: Chief Executive Officer, Director
Address: 2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, THE WOODLANDS
Signature: /s/ Michael Exton, Ph.D.
Signature date: 17 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LXRX transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +862,440
Change %
Price: $0.000000
Shares after: 862,440
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 862,440
Exercise price
Footnotes: F1, F2

LXRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +1,293,670
Change %
Price: $0.000000
Shares after: 1,293,670
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,293,670
Exercise price: $1.37
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of common stock.

Footnote F2

Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.

Footnote F3

Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.